Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Related Articles
Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine
Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians…April 13, 2021
Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care
Company’s ECG-AI algorithm enables earlier heart failure detectionNovember 05, 2024
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions…March 16, 2026
Anumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and…January 12, 2026